Pharmacogenetic tests are also crucial in oncology, where targeted therapies are becoming increasingly common. New drugs designed to treat cancers such as breast, colon, lung cancers, gastrointestinal tumors, and malignant melanomas require precise genetic profiling to identify which patients will benefit most.
At Genetiks, we perform essential tests to detect mutations in HER2, ALK-EML4, ROS1, PDL1&2, EGFR, KRAS, NRAS, BRAF, C-KIT, and PDGFRA. Our comprehensive tests which based on sequencing technology (CGP and molecular profiling) provides information about the molecular signature of the tumor. These tests have become standard practice before administering these advanced therapies, ensuring that treatment is tailored to the genetic profile of the tumor, thereby enhancing the effectiveness of cancer treatment decreasing the side effects and toxicity of the medication.